Advertisement
Advertisement
TSHA
Taysha Gene Therapies, Inc. Common Stock
6.68
USDSponsored
+0.31
+4.87%
Aug 11, 16:00 UTC -4
Closed
After-Market
6.33
-0.35
-5.27%
TSHA Earnings Reports
Positive Surprise Ratio
TSHA beat 11 of 24 last estimates.
46%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$693.60K
/-$0.12
Implied change from Q2 26 (Revenue/ EPS)
--
/-7.69%
Implied change from Q3 25 (Revenue/ EPS)
--
/+33.33%
Taysha Gene Therapies, Inc. Common Stock earnings per share and revenue
On Aug 11, 2026, TSHA reported earnings of -0.13 USD per share (EPS) for Q2 26, missing the estimate of -0.11 USD, resulting in a -9.34% surprise. Revenue reached --, compared to an expected 693.60 thousand, with a -100.00% difference.
Looking ahead to Q3 26, 11 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 693.60 thousand USD, implying an decrease of -7.69% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Personalis, Inc. Common Stock
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.30
Surprise
-13.16%
Amphastar Pharmaceuticals, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.63
Actual
$0.91
Surprise
+43.87%
Teva Pharmaceutical Industries Limited - ADR
Report Date
Jul 29, 2026 For Q2 26
Estimate
$0.25
Actual
$0.02
Surprise
-92.05%
BridgeBio Pharma, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.59
Actual
-$0.78
Surprise
-31.07%
Supernus Pharmaceuticals, Inc.
Report Date
Aug 03, 2026 For Q2 26
Estimate
$0.42
Actual
$0.53
Surprise
+23.72%
Bausch Health Companies Inc
Report Date
Jul 29, 2026 For Q2 26
Estimate
$1.04
Actual
$1.26
Surprise
+20.34%
FAQ
What were Taysha Gene Therapies, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Taysha Gene Therapies, Inc. Common Stock reported EPS of -$0.13, missing estimates by -9.34%, and revenue of $0.00, -100% below expectations.
How did the market react to Taysha Gene Therapies, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Taysha Gene Therapies, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Taysha Gene Therapies, Inc. Common Stock's next earnings report?
Based on 11
analysts, Taysha Gene Therapies, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $693.60K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement